Where he showed this graph from from the Journal Nature (10-19-09), “Avoiding Premature Licensing” that shows the inflection point with respect to stages of clinical trial phase development:
This observation by SunStar, “Peregrine is at an inflection point. We are at the end of three separate phase 2 cancer trials that will provide the first look at expanded numbers of patients with respect to safety and efficacy. We have already seen some superb results with bavituximab in these combination cancer trials. Now all three trials have finished enrolling. This is the statistical point where the value of a successfully advancing drug candidate soars with respect to partnering or buyout.”
Market Data 
Markets 
AI
